Avacta Share Price (AVCT)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Avacta Group Plc	LSE:AVCT	London	Ordinary Share	GB00BYYW9G87	ORD 10P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.0%	17.50	15,500	08:00:00

Bid Price		Offer Price	High Price	Low Price	Open Price
17.00		18.00	17.50	17.50	17.50

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	2.76	-10.39	-13.49		20

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
15:49:21	O	1,000	17.40	GBX

Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Agronomics (ANIC), Geiger Counter (GCS)

Avacta (AVCT) Latest News

Avacta News

Date	Time	Source	Headline
10/10/2019	11:24	ALNC	Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates
10/10/2019	08:41	BW	Avacta Group plc Enters Collaboration and Option Agreement With ADC..
10/10/2019	07:27	ALNCF	Alliance News Flash Headline
10/10/2019	07:00	UKREG	Avacta Group PLC Collaboration with ADC Therapeutics
05/8/2019	09:05	UKREG	Avacta Group PLC Second Price Monitoring Extn
05/8/2019	09:00	UKREG	Avacta Group PLC Price Monitoring Extension
29/7/2019	07:01	RNSNON	Avacta Group PLC Avacta's CEO to Present at Biotech Investor Day
20/6/2019	12:25	ALNC	Avacta To Partner With Selexis On Cell Line Manufacturing Of AVA004
20/6/2019	07:00	UKREG	Avacta Group PLC Avacta and Selexis Partner to Develop Cell Line
19/6/2019	07:00	RNSNON	Avacta Group PLC Turner Pope Investor Evening

More Avacta News

Avacta Takeover Rumours

Avacta (AVCT) Share Charts

1 Year Avacta Chart

1 Month Avacta Chart

Intraday Avacta Chart

Avacta (AVCT) Discussions and Chat

Avacta Forums and Chat

Date	Time	Title	Posts
15/10/2019	10:52	Avacta – Innovative and Disruptive Technologies for Global Health Markets	2,679
01/5/2019	14:32	Avacta Group at the UK Investor Show	-
10/7/2017	12:54	Avacta – Unique and innovative technology blipping on big pharma’s radar	1,739
13/1/2012	15:28	Avacta Group - Broadening their horizons	1
13/6/2011	12:22	'Best of Palls' - Avacta Group plc	-

Add a New Thread

Avacta (AVCT) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2019-10-16 14:49:22	17.40	1,000	174.00	O
2019-10-16 13:37:48	17.40	10,500	1,827.00	O
2019-10-16 11:27:39	17.01	4,000	680.40	O

View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

Date	Subject
16/10/2019 09:20	Avacta Daily Update: Avacta Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 17.50p. Avacta Group Plc has a 4 week average price of 17.25p and a 12 week average price of 17.25p. The 1 year high share price is 49p while the 1 year low share price is currently 17.25p. There are currently 115,956,471 shares in issue and the average daily traded volume is 364,415 shares. The market capitalisation of Avacta Group Plc is £20,292,382.43. Read Full Thread Reply
11/10/2019 13:32	chilly0: Suffering is an inevitable outcome for any AIM investor. Either embrace the pain or quit. 50p bid from moderna or any other company would be a steal and in my opinion not good. The only question is does the technology work and can the board commercialize within an acceptable time period. Some investor have been negative re the board but they have done what they said they would do. Obviously this is still a waiting game for a positive outcome but if and when that materialises then these share will rerate quick. I'm not happy where the share price is but investing in lottery ticket companies is not easy Read Full Thread Follow Reply
10/10/2019 09:12	74tom: @Babbler, I think the management see the market as a bottomless pit & that if they continue to sign new deals or release exciting data they will always be able to raise more cash. Whilst this has been true to date, the impact of such a strategy on the share price is evident to everyone. Read Full Thread Follow Reply
12/9/2019 00:41	danatkins: Tony I think you are a wiser individual. Company has no control over the share price. Biotech have been hit hard the last few years. look at etf labu says it all. the co is in easily stage development with risk attached same as all biotech companies Read Full Thread Follow Reply
02/8/2019 19:51	lantanatony: Can anyone please explain how Avacta are going to fund in house clinical trials with a share price of 25pence? Share holders were told 2019 would be most exciting year!..... Read Full Thread Follow Reply
01/7/2019 22:33	rubstick: They are going to have to raise money and at this share price that will be expensive. That is the risk of this company and it is quite possible existing holders could be diluted significantly. Read Full Thread Follow Reply
01/7/2019 14:42	lantanatony: Bumpa , That's why I feel Avacta should try to raise funds in America. But you need a solid story and good Broker Do Avacta have either? The share price says NO! Read Full Thread Follow Reply
07/5/2019 12:41	danatkins: Agree re don't sell and wait it out games being played. Very low volume. If you believe in the tech then hold and add if you feel comfortable. The share price and the tech are not the same. I invested because I believe in the tech not of share price. Weak hands will get flushed out Read Full Thread Follow Reply
23/1/2019 19:42	cf456: Poor attempt at a deramp there. Today's volume is low. There has been no heavy selling, just a little bit of profit taking in a strong uptrend. The price has moved up 100% since December and in the past couple of days hit multi-month highs. Quite understandable that some feel tempted to take profits. The fun has barely started here. LG Chem the first of multiple anticipated deals. Looking forward to much greater share price appreciation in the coming months. Fully expect retracements along the way. Nothing moves in a straight line. But the trend is now up and multiples of the current share price over time can be expected. Read Full Thread Follow Reply
30/12/2018 15:37	bumpa33: Malcolm Stacey, long time follower of AVCT gives his reasoning for picking them as one of his tips of the year. Nothing we don’t really know already... Between now and January 2nd we shall be publishing more than 20 share tips of the year – buys and sells. Second up is one from Malcolm Stacey. Hello Share Trouncers. Investing in medical pioneers - especially smaller ones - is one of the riskiest ploys you can adopt in Shareland. But the rewards are usually glittering. Probably the best-placed modest pharma in my collection at the mo is Avacta (AVCT). For a long time now the share price has slowly decayed. That’s the fate of many a penny share which hasn’t been able to publish recent good news. However, all that’s changed in the last few weeks. Firstly, let me explain why Avacta has been raising interest in the medical world. It produces affimers. These are alternatives to antibodies. The latter are produced in animals to treat diseases, some of them serious. The advantages of artificial antibodies is that they don't have to be produced in animals, they are more stable and probably cheaper to develop. The market is worth billions and a big South Korean pharma, LG Group, has realised this. It is investing up to £180 million pounds in Avacta. And that’s good because we all know medical research is acutely expensive. On top of this, the deal allows the Wetherby firm to collect royalties. On the heels of this welcome news came tiding that a big new cheese was being appointed from the Swiss giant Roche. He is Doctor Jose Saro, who’ll oversee the affirmer project. And by all accounts this chap really knows how to develop new treatments. These people would not be scrambling onto Avacta’s bandwagon if they had not researched the possibilities throughly. As lay people we cannot make a judgement on the usefulness of affimers. But these heavy-hitters know their stuff and we can probably attach high value to their support. The share price leapt on December’s news. But it’s fallen slightly since. And I really don't think the market has realised the potential - yet. Read Full Thread Follow Reply
28/12/2018 10:28	74tom: Disagree that it depends on the markets, unless we have an armageddon event. With a 33m Mcap if the positive news flow continues in 2019 the current share price will increase considerably. Trading is fine but it’s such behaviour that has held the current share price below 33p since the LG deal, as every time we get momentum a rash of 10% profit taking occurs. The simplest rule that allows the price to rise and derisks fully it to sell half when the price doubles, leaving a free carry on the remainder. Read Full Thread Follow Reply

Avacta share price data is direct from the London Stock Exchange

Your Recent History

LSE

AVCT

Avacta

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20191017 01:03:30